Free Trial
→ Elon Musk's Intel Deal Already Jumped 177 Percent This Year (From Brownstone Research) (Ad)tc pixel
NASDAQ:VALN

Valneva Q3 2026 Earnings Date & Estimates

Valneva logo
$5.63 +0.12 (+2.18%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$5.78 +0.15 (+2.58%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Valneva is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. The conference call is scheduled for November 24, 2026 at 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Valneva in Q3 2026

Valneva is expected to post earnings of -$0.23 per share on revenue of $43.67 million. In the same quarter a year earlier Valneva reported -$0.61 per share on revenue of $34.01 million. Valneva last reported on August 14, 2026, posting -$0.40 per share and missing the -$0.1886 consensus estimate. Valneva has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.23
Expected Revenue
$43.67 million
Prior-Year EPS
-$0.61
Prior-Year Revenue
$34.01 million
Expected Revenue Growth
+28.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.40 (Missed by -$0.2114)
Last Quarter Revenue
$39.37 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Valneva Q3 2026 Earnings FAQ

Valneva (NASDAQ:VALN) is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Valneva's Q3 2026 earnings conference call is scheduled for Tuesday, November 24, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Valneva to post earnings of -$0.23 per share for Q3 2026.

The consensus revenue estimate for Valneva is $43.67 million for Q3 2026.

Valneva Earnings Headlines

Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
November 4 at 11:45 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395665/0/en/valneva-to-report-nine-month-2026-consolidated-financial-results-on-november-24-2026.html
Contrasting Valneva (NASDAQ:VALN) & Atara Biotherapeutics (NASDAQ:ATRA)
October 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31161736
Elon Musk's Intel Deal Already Jumped 177 Percent This Year
Elon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the analyst who flagged Nvidia in 2016 before its 37,800% run, says Musk may announce a new AI partnership any day.tc pixel
November 5 at 1:00 AM  |  Brownstone Research (Ad)
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
October 21, 2026  |  yahoo.comhttps://www.yahoo.com/news/science/articles/mhra-revokes-approval-valneva-ixchiq-100856322.html
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380957/0/en/valneva-to-present-and-hold-investor-meetings-at-upcoming-u-s-and-european-healthcare-conferences.html
Valneva SE Provides Update On IXCHIQ In The United Kingdom
October 9, 2026  |  marketscreener.comM
See More Valneva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Valneva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Valneva and other key companies, straight to your email.

About Valneva

Valneva (NASDAQ:VALN) SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines vaccine research and development with in-house manufacturing and commercial operations serving public health agencies, travel medicine providers and private healthcare markets.

Valneva’s marketed products include IXIARO and JESPECT for the prevention of Japanese encephalitis, and DUKORAL, an oral vaccine used to help prevent cholera and, in some markets, enterotoxigenic Escherichia coli-related travelers’ diarrhea. The company also developed IXCHIQ, a vaccine designed to protect adults against chikungunya, a mosquito-borne viral disease. Product availability and regulatory approvals vary by geography.

Headquartered in France, Valneva has roots in the combination of French biotechnology company Vivalis and Austrian vaccine developer Intercell, which formed the company in 2013. It has developed and supplied vaccines across European, North American and international travel-health markets, with operations and commercial partnerships supporting distribution in multiple regions.

View Valneva Profile
Earnings Tools